This year's BIO show, May 19-22 in Atlanta, drew 14,352 attendees.
This page will provide news, blogs, articles, video and audio coverage from BIO 2009. Check back for updates.
Think QbD is daunting? Double that for the biotech arena.Click Here
The pharmaceutical industry is under extraordinary strain. Facing the wrath of consumers because of the cost of products, constantly answering the questions of state and federal legislators looking to control health care costs, and losing value in the marketplace, the industrys hands are more than full.Click Here
U.S. regulatory approvals for new biopharmaceuticals nearly doubled in the last decade, compared to the 1990s, according to the Tufts Center for the Study of Drug Development, but drug developers "face substantial challenges" if they are to maintain that pace, the study's author says.Click Here
In todays pharma world, speed to market often trumps QbD, while QbD can crowd out Lean and other operational excellence initiatives. It doesnt have to be so, says Tunnell Consultings Bryan Winship, who also explains how to avoid the middle-management black hole in QbD efforts.Listen Now
Catalent Pharmaceuticals new GPEx technology is a gene expression method which inserts genes into target cells, eliminating the need for markers. Mike Jenkins, GM of Catalents Middleton, Wis., facility explains how GPEx helps manufacturers turn the corner, quickly, from research to development.Listen Now
Savara, Inc. out of Austin, Texas, specializes in reformulating successful drugs for use in standard inhalable devices, by engineering the nano whiffle ball out of the drug itself, or a combination of drugs. Executive chairman Rob Neville explains in this audio.Listen Now